226 related articles for article (PubMed ID: 36674615)
1. Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a).
Stellato M; Buti S; Maruzzo M; Bersanelli M; Pierantoni F; De Giorgi U; Di Napoli M; Iacovelli R; Vitale MG; Ermacora P; Malgeri A; Maiorano BA; Prati V; Mennitto A; Cavo A; Santoni M; Carella C; Fratino L; Procopio G; Verzoni E; Santini D
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674615
[TBL] [Abstract][Full Text] [Related]
2. Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.
Dizman N; Austin M; Considine B; Jessel S; Schoenfeld D; Merl MY; Hurwitz M; Sznol M; Kluger H
Clin Genitourin Cancer; 2023 Apr; 21(2):221-229. PubMed ID: 36681606
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
4. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Tarazi JC; Duggan W; Perini R; Thakur M; Fernandez KC; Choueiri TK
Eur J Cancer; 2021 Mar; 145():1-10. PubMed ID: 33412465
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.
Tamada S; Kondoh C; Matsubara N; Mizuno R; Kimura G; Anai S; Tomita Y; Oyama M; Masumori N; Kojima T; Matsumoto H; Chen M; Li M; Matsuda K; Tanaka Y; Rini BI; Uemura H
Int J Clin Oncol; 2022 Jan; 27(1):154-164. PubMed ID: 34800178
[TBL] [Abstract][Full Text] [Related]
6. A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non-clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus.
Park I; Lee SH; Lee JL
Clin Genitourin Cancer; 2018 Oct; 16(5):e997-e1002. PubMed ID: 29903415
[TBL] [Abstract][Full Text] [Related]
7. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.
McDermott DF; Lee JL; Ziobro M; Suarez C; Langiewicz P; Matveev VB; Wiechno P; Gafanov RA; Tomczak P; Pouliot F; Donskov F; Alekseev BY; Shin SJ; Bjarnason GA; Castellano D; Silverman RK; Perini RF; Schloss C; Atkins MB
J Clin Oncol; 2021 Mar; 39(9):1029-1039. PubMed ID: 33529058
[TBL] [Abstract][Full Text] [Related]
8. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.
Negrier S; Rioux-Leclercq N; Ferlay C; Gross-Goupil M; Gravis G; Geoffrois L; Chevreau C; Boyle H; Rolland F; Blanc E; Ravaud A; Dermeche S; Flechon A; Albiges L; Pérol D; Escudier B;
Eur J Cancer; 2020 Apr; 129():107-116. PubMed ID: 32146304
[TBL] [Abstract][Full Text] [Related]
9. Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.
Barata PC; Chehrazi-Raffle A; Allman KD; Asnis-Alibozek A; Kasturi V; Pal SK
Oncologist; 2023 Oct; 28(10):894-900. PubMed ID: 37315114
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
Plimack ER; Powles T; Stus V; Gafanov R; Nosov D; Waddell T; Alekseev B; Pouliot F; Melichar B; Soulières D; Borchiellini D; McDermott RS; Vynnychenko I; Chang YH; Tamada S; Atkins MB; Li C; Perini R; Molife LR; Bedke J; Rini BI
Eur Urol; 2023 Nov; 84(5):449-454. PubMed ID: 37500340
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.
Chahoud J; Msaouel P; Campbell MT; Bathala T; Xiao L; Gao J; Zurita AJ; Shah AY; Jonasch E; Sharma P; Tannir NM
Oncologist; 2020 Mar; 25(3):252-258. PubMed ID: 32162795
[TBL] [Abstract][Full Text] [Related]
13. Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.
Facchini G; Rossetti S; Berretta M; Cavaliere C; Scagliarini S; Vitale MG; Ciccarese C; Di Lorenzo G; Palesandro E; Conteduca V; Basso U; Naglieri E; Farnesi A; Aieta M; Borsellino N; La Torre L; Iovane G; Bonomi L; Gasparro D; Ricevuto E; De Tursi M; De Vivo R; Lo Re G; Grillone F; Marchetti P; De Vita F; Scavelli C; Sini C; Pisconti S; Crispo A; Gebbia V; Maestri A; Galli L; De Giorgi U; Iacovelli R; Buonerba C; Cartenì G; D'Aniello C
J Transl Med; 2019 Aug; 17(1):296. PubMed ID: 31464635
[TBL] [Abstract][Full Text] [Related]
14. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI
Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205
[TBL] [Abstract][Full Text] [Related]
15. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
16. Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
Kato T; Nakano Y; Hongo F; Katano H; Miyagawa T; Ueda K; Azuma H; Nozawa M; Hinata N; Hori J; Otoshi T; Shimizu N; Aizawa M; Osada S; Matsui A; Oya M; Eto M; Tomita Y; Shinohara N; Uemura H
Int J Urol; 2024 Mar; 31(3):265-272. PubMed ID: 38110838
[TBL] [Abstract][Full Text] [Related]
17. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.
Hutson TE; Michaelson MD; Kuzel TM; Agarwal N; Molina AM; Hsieh JJ; Vaishampayan UN; Xie R; Bapat U; Ye W; Jain RK; Fishman MN
Eur Urol; 2021 Aug; 80(2):162-170. PubMed ID: 33867192
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.
Tannir NM; Plimack E; Ng C; Tamboli P; Bekele NB; Xiao L; Smith L; Lim Z; Pagliaro L; Araujo J; Aparicio A; Matin S; Wood CG; Jonasch E
Eur Urol; 2012 Dec; 62(6):1013-9. PubMed ID: 22771265
[TBL] [Abstract][Full Text] [Related]
19. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
[TBL] [Abstract][Full Text] [Related]
20. Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27.
Stellato M; Buti S; Maruzzo M; Bassanelli M; Bersanelli M; Napoli MD; Dionese M; Fanelli M; Filippi R; Fotia G; Galli L; Grillone F; Maffezzoli M; Maiorano BA; Nasso C; Rebuzzi SE; Lalli L; Roviello G; Sorarù M; Vincenzi B; Procopio G; Verzoni E
Clin Genitourin Cancer; 2024 Jun; 22(3):102078. PubMed ID: 38631104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
